Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PYC-001

Phase 1Small molecule

PPYC Therapeutics

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

OPA1 Gene MutationActive, not recruiting

OPA1 Gene MutationPhase 1

Active, not recruiting

Timeline

Expected Milestones

Q4 2029

Phase 1Active, not recruiting

OPA1 Gene Mutation

NCT06461286

PreclinicalRecruiting

OPA1 Gene Mutation

NCT06970106

Clinical

Trials by Indication[1]

OPA1 Gene Mutation2 trials

A Phase 1a Open-Label, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered PYC-001 in Participants With Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy

Active, not recruiting·PPYC Therapeutics·Phase 1·NCT06461286·18 enrolled

A Phase 1b Open-Label, Randomized, Single Dose and Repeat Dose Study to Evaluate the Single and Repeat Dose Safety and Tolerability of Intravitreally Administered PYC-001 in Participants With Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy

Recruiting·PPYC Therapeutics·Preclinical·NCT06970106·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PYC-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PYC-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PYC-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PYC Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPYC Therapeutics

Related News